BBIO (STOCKS)
BridgeBio Pharma, Inc. Common Stock
$68.000000
+1.200000 (+1.80%)
Prev close: $66.800000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Neil Kumar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $13,322.48M
- Employees
- 730
- P/E (TTM)
- -18.15
- P/B (TTM)
- -5.84
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
19
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.84 | $-0.69 | -0.1479 | -21.37% |
|
Dec 2025 (Q4)
|
$-1.00 | $-0.76 | -0.2430 | -32.10% |
|
Sep 2025 (Q3)
|
$-0.95 | $-0.91 | -0.0436 | -4.81% |
|
Jun 2025 (Q2)
|
$-0.95 | $-0.86 | -0.0898 | -10.44% |
Financial Statements
| Revenues | $579.96M |
| Benefits Costs and Expenses | $1.31B |
| Cost Of Revenue | $28.26M |
| Costs And Expenses | $1.10B |
| Gross Profit | $551.70M |
| Nonoperating Income/Loss | -$204.46M |
| Operating Expenses | $1.08B |
| Selling, General, and Administrative Expenses | $588.76M |
| Research and Development | $467.16M |
| Operating Income/Loss | -$525.00M |
| Income/Loss Before Equity Method Investments | -$654.12M |
| Income/Loss From Continuing Operations After Tax | -$729.89M |
| Income/Loss From Continuing Operations Before Tax | -$729.45M |
| Income/Loss From Equity Method Investments | -$75.34M |
| Net Income/Loss | -$729.89M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$8.33M |
| Net Income/Loss Attributable To Parent | -$721.55M |
| Net Income/Loss Available To Common Stockholders, Basic | -$721.55M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.73 |
| Diluted Earnings Per Share | -$3.73 |
| Basic Average Shares | 386,502,333 |
| Diluted Average Shares | 386,502,333 |
| Assets | $1.37B |
| Current Assets | $1.24B |
| Inventory | $32.98M |
| Other Current Assets | $1.21B |
| Noncurrent Assets | $129.68M |
| Fixed Assets | $4.94M |
| Intangible Assets | $27.36M |
| Other Non-current Assets | $97.38M |
| Liabilities | $3.64B |
| Current Liabilities | $816.37M |
| Accounts Payable | $29.06M |
| Wages | $39.34M |
| Other Current Liabilities | $747.98M |
| Noncurrent Liabilities | $2.82B |
| Long-term Debt | $2.65B |
| Other Non-current Liabilities | $170.61M |
| Redeemable Noncontrolling Interest | -$951.00K |
| Equity | -$2.27B |
| Equity Attributable To Noncontrolling Interest | $10.44M |
| Equity Attributable To Parent | -$2.28B |
| Temporary Equity | -$951.00K |
| Liabilities And Equity | $1.37B |
| Net Cash Flow From Operating Activities | -$443.95M |
| Net Cash Flow From Operating Activities, Continuing | -$443.95M |
| Net Cash Flow From Investing Activities | -$65.63M |
| Net Cash Flow From Investing Activities, Continuing | -$65.63M |
| Net Cash Flow From Financing Activities | $848.86M |
| Net Cash Flow From Financing Activities, Continuing | $848.86M |
| Net Cash Flow | $339.28M |
| Net Cash Flow, Continuing | $339.28M |
| Comprehensive Income/Loss | -$729.89M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$8.33M |
| Comprehensive Income/Loss Attributable To Parent | -$721.56M |
| Other Comprehensive Income/Loss | -$8.00K |